Cytomegalovirus infection in solid organ transplant recipients

Clinical Microbiology and Infection

Volumn 20, Issue s7, 2014, Pages 19-26

  Lumbreras, C ^a   Manuel, O ^b   Len, O ^c   ten Berge, I J M ^d   Sgarabotto, D ^e   Hirsch, H H ^f,g  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Cytomegalovirus; Organ transplantation; Prevention; Risk factors; Treatment

Indexed keywords

ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

CYTOMEGALOVIRUS INFECTION; GRAFT RECIPIENT; HUMAN; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PATIENT CARE; REVIEW; RISK FACTOR; SOLID ORGAN TRANSPLANTATION; T LYMPHOCYTE; CYTOMEGALOVIRUS INFECTIONS; IMMUNOCOMPROMISED PATIENT; OPPORTUNISTIC INFECTIONS;

CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; TRANSPLANT RECIPIENTS;

EID: 84908177142     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12594     Document Type: Review

References (61)

1. Rosenthal SL, Stanberry LR, Biro FM et al. Seroprevalence of herpes simplex virus type 1 and 2 and cytomegalovirus in adolescents. Clin Infect Dis 1997; 24: 135-139.
2. Sinzger C, Grefte A, Plachter B, Gouw AS, The TH, Jahn G. Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. J Gen Virol 1995; 76: 741-750.
3. Wiertz E, Hill A, Tortorella D, Ploegh H. Cytomegaloviruses use multiple mechanisms to elude the host immune response. Immunol Lett 1997; 57: 213-216.
4. Gamadia LE, Rentenaar RJ, van Lier RA, ten Berge IJ. Properties of CD4(+) T cells in human cytomegalovirus infection. Hum Immunol 2004; 65: 486-492.
5. van Leeuwen EM, de Bree GJ, ten Berge IJ, van Lier RA. Human virus-specific CD8+ T cells: diversity specialists. Immunol Rev 2006; 211: 225-235.
6. Remmerswaal EB, Havenith SH, Idu MM et al. Human virus-specific effector-type T cells accumulate in blood but not in lymph nodes. Blood 2012; 119: 1702-1712.
7. Hertoghs KM, Moerland PD, van Stijn A et al. Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation. J Clin Invest 2010; 120: 4077-4090.
8. ter Meulen CG, Wetzels JF, Hilbrands LB. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplant 2000; 15: 711-714.
9. Nashan B, Gaston R, Emery V et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012; 93: 1075-1085.
10. Klarenbeek PL, Remmerswaal EB, ten Berge IJ et al. Deep sequencing of antiviral T-cell responses to HCMV and EBV in humans reveals a stable repertoire that is maintained for many years. PLoS Pathog 2012; 8: e1002889.
11. Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 7: 779-795.
12. 0Andrews PA, Emery VC, Newstead C. Summary of British transplantation society guidelines for the prevention and management of CMV disease after solid organ transplantation. Transplantation 2011; 92: 1181-1187.
13. de la Torre-Cisneros J, Fariñas MC, Castón JJ et al. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011; 29: 735-758.
14. Cantisán S, Lara R, Montejo M et al. Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant 2013; 13: 738-745.
15. Freyer JF, Heath AB, Anderson R, Minor PD, and the collaborative study group. Collaborative study to evaluate the proposed 1st WHO international standard for human cytomegalovirus for nucleic acid amplification-based assays. WHO/BS/10.2138, pp. 1-40. Geneva, Switzerland, 18-22 October 2010.
16. Clinical and Laboratory Standards Institute (CLSI). Metrological traceabilityand its implementation; a report. CLSI document X5-R, Vol 26, No 10. ISBN 1-56238-598-4.
17. Hirsch HH, Lautenschlager I, Pinsky BA et al. An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis 2013; 56: 367-373.
18. Cardeñoso L, Pinsky BA, Lautenschlager I et al. CMV antigenemia and quantitative viral load assessments in hematopoietic stem cell transplant recipients. J Clin Virol 2013; 56: 108-112.
19. Mannonen L, Loginov R, Helanterä I et al. Comparison of two quantitative real-time CMV-PCR tests calibrated against the 1st WHO international standard for viral load monitoring of renal transplantpatients. J Med Virol 2013; 86: 576-584.
20. Kraft CS, Armstrong WS, Caliendo AM. Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective. Clin Infect Dis 2012; 54: 1793-1797.
21. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
22. Sester M, Sester U, Gartner BC, Girndt M, Meyerhans A, Kohler H. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol 2002; 13: 2577-2584.
23. Egli A, Binet I, Binggeli S et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008; 6: 29-34.
24. Weseslindtner L, Kerschner H, Steinacher D et al. Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients. Am J Transplant 2012; 12: 2172-2179.
25. Manuel O, Husain S, Kumar D et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013; 56: 817-825.
26. Sagedal S, Nordal KP, Hartmann A et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000; 70: 1166-1174.
27. Manuel O, Asberg A, Pang X et al. Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid organ transplant recipients with cytomegalovirus disease. Clin Infect Dis 2009; 49: 1160-1166.
28. Hooks MA, Perlino CA, Henderson JM, Millikan WJ Jr, Kutner MH. Prevalence of invasive cytomegalovirus disease with administration of muromonab CD-3 in patients undergoing orthotopic liver transplantation. Ann Pharmacother 1992; 26: 617-620.
29. Charpentier B, Rostaing L, Berthoux F et al. A three arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003; 75: 844-851.
30. Peleg AY, Husain S, Kwak EJ et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44: 204-212.
31. Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000; 14: 136-138.
32. Bernabeu-Wittel M, Naranjo M, Cisneros JM et al. Infections in renal transplant recipients receiving mycophenolate versus azathioprine-based immunosuppression. Eur J Clin Microbiol Infect Dis 2002; 21: 173-180.
33. DesJardin JA, Gibbons L, Cho E et al. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J Infect Dis 1998; 178: 1783-1786.
34. Cervera C, Lozano F, Saval N et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 2007; 83: 1493-1500.
35. Cervera C, Balderramo D, Suárez B et al. Donor mannose-binding lectin gene polymorphisms influence the outcome of livertransplantation. Liver Transpl 2009; 15: 1217-1224.
36. Kijpittayarit S, Eid AJ, Brown RA, Paya CV, Razonable RR. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis 2007; 44: 1315-1320.
37. San Juan R, Aguado JM, Lumbreras C et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008;47:875-882.
38. Fernández-Ruiz M, López-Medrano F, Varela-Peña P et al. Monitoring of immunoglobulin levels identifies kidney transplant recipients at high risk of infection. Am J Transplant 2012; 12: 2763-2773.
39. Florescu DF, Kalil AC, Qiu F, Schmidt CM, Sandkovsky U. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis Am J Transplant 2013; 13: 2601-2610.
40. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43: 869-880.
41. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870-880.
42. Khoury JA, Storch GA, Bohl DL et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134-2143.
43. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8: 975-983.
44. Manuel O, Kralidis G, Mueller NJ et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid-organ transplant recipients. Am J Transplant 2013; 13: 2402-2410.
45. Benmarzouk-Hidalgo OJ, Cordero E, Martín-Peña A et al. Prevention of cytomegalovirus disease using pre-emptive treatment after solid organ transplant in patients at high risk for cytomegalovirus infection. Antivir Ther 2009; 14: 641-647.
46. Humar A, Lebranchu Y, Vincenti F et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237.
47. Palmer SM, Limaye AP, Banks M et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152: 761-769.
48. Le Page AK, Jager MM, Kotton CN, Simoons-Smit A, Rawlinson WD. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. Transplantation 2013; 95: 1455-1460.
49. Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients. Transplantation 2011; 91: 251-255.
50. Asberg A, Humar A, Rollag H et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106-2113.
51. Asberg A, Humar A, Jardine AG et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9: 1205-1213.
52. Caldés A, Gil-Vernet S, Armendariz Y et al. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics. Transpl Infect Dis 2009; 12: 204-212.
53. Limaye AP. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients. Semin Respir Infect 2002; 17: 265-273.
54. Marchetti S, Santangelo R, Manzara S, D'Onghia S, Fadda G, Cattani P. Comparison of real-time PCR and pp65 antigen assays for monitoring the development of cytomegalovirus disease recipients of solid organ and bone marrow transplants. New Microbiol 2011; 34: 157-164.
55. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186: 829-833.
56. Razonable RR, Åsberg A, Rollag H et al. Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the world health organization international standard is predictive of CMV disease resolution in transplant recipients. Clin Infect Dis 2013; 56: 1546-1553.
57. Mattes FM, Hainsworth EG, Geretti AM et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 2004; 189: 1355-1361.
58. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Emergence of drug resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 22: 162-170.
59. Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 2002; 34: 1337-1341.
60. Marty FM, Winston DJ, Rowley SD et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369: 1227-1236.
61. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011; 85: 10884-10893.